Seeking Alpha

NPS Pharmaceuticals (NPSP): Q1 EPS of -$0.12 misses by $0.01. Revenue of $22.2M (-3% Y/Y) misses...

NPS Pharmaceuticals (NPSP): Q1 EPS of -$0.12 misses by $0.01. Revenue of $22.2M (-3% Y/Y) misses by $1.7M. (PR)
Comments (2)
  • SteveBoulay
    , contributor
    Comment (1) | Send Message
     
    This stock should be a double or more over the next 6-12 months on GATTEX approval, NATPARA approval and return of Sensipar Royatlies starting in 2013 mid-year. Assumsing a minimum of 5 years patent protection Sensipar should net 500m to the bottom line for NPSP
    4 May 2012, 04:53 AM Reply Like
  • Christopher Nassar
    , contributor
    Comments (6) | Send Message
     
    Still a very good stock to hold long-term.
    4 May 2012, 08:13 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|